IL-17 Inhibitor Shows Greater Cumulative Benefit Than Ustekinumab for Psoriasis

Patients treated with brodalumab for moderate-to-severe psoriasis had significantly higher levels of skin clearance, longer sustained response, and greater cumulative treatment benefit compared with those treated with ustekinumab, according to a study published online in the Journal of the European Academy of Dermatology and Venereology.

The findings stem from analyses of data from the brodalumab phase 3 AMAGINE-2 and AMAGINE-3 trials.

By week 52, 51% of patients treated with brodalumab achieved complete skin clearance compared with 28% of patients treated with ustekinumab, according to the study. Significant differences in the proportion of patients achieving complete skin clearance between the treatment groups emerged as early as week 4.
____________________________________________________
You may also like...
The Psoriasis and Comorbidity Series: Understanding the Link between Psoriasis, Diabetes, and Obesity
Updates in Psoriasis Treatment
Investigational Biologic Shows Promise for Psoriasis
____________________________________________________

In area-under-the-curve analysis, the cumulative clinical benefit considering rapidity, frequency, and sustainability of response through week 52 was 69% higher with brodalumab.

The study also found patients treated with brodalumab were significantly more likely to achieve complete skin clearance at least once over 52 weeks compared with patients treated with ustekinumab.

“Once response was achieved, brodalumab patients had a low likelihood of failure or need for rescue,” the researchers stated.

—Jolynn Tumolo

Reference

Warren RB, Hansen JB, Reich K, Paul C, Puig L. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. J Eur Acad Dermatol Venereol. Published online July 14, 2020. 2020;10.1111/jdv.16816. doi:10.1111/jdv.16816